BioAxone Biosciences Inc. is a privately owned American Corporation with a focus on bringing drugs to market for unmet medical needs. Cethrin™ is BioAxone’s lead protein compound that has completed a Phase 2a study in patients with spinal injury. BioAxone has expertise in protein drugs and it has an estate of issued patents that protects its lead compound and its use in various medical conditions. BioAxone also has patented small molecule inhibitors and a transport sequence available for licensing.
The company CEO, Lisa McKerracher, is an experienced scientist and entrepreneur who led early development of the technology, scale-up manufacturing, initiation of clinical trials, and robust pipeline development. BioAxone BioSciences Inc (USA) has acquired all of the assets of the previous company that she Founded in Canada (BioAxone Therapeutic Inc). The new company has a mission to ensure that Cethrin development proceeds rapidly to commercialization to be available to improve recovery for neurotrauma patients.
BioAxone BioSciences is exploring other ways that Cethrin may help restore function in injury and disease. On the research side, BioAxone has completed proof-of-concept for use of its recombinant protein products for bone repair, traumatic brain injury, degenerative eye disease, and glioblastoma. The development of related technologies will be focused to extending the market for unmet medical needs.
The Road to Repair: A bit of History
Cethrin was originally developed by BioAxone Therapeutic Inc. , a spin-out company from Université de Montréal, under Dr. Lisa McKerracher’s scientific leadership. Her group had shown that targeting the Rho signaling pathway could improve outcomes after spinal cord injury. To help patients with SCI, Dr. McKerracher launched BioAxone to test Rho inactivation in clinical trials. BioAxone Therapeutic Inc (Canada) initiated these trials, and then the company management licensed the technology to Alseres. In 2010 BioAxone recuperated the license, and in 2011 returned the rights to the Founder. With the formation of BioAxone BioSciences Inc , the goal is to accelerate the development timeline. In the next year we will launch the 2b clinical study in acute SCI, and also initiate 1/2a clinical studies in eye disease that had been planned .